Legacy Capital Wealth Partners LLC Has $487,000 Holdings in AstraZeneca PLC (NASDAQ:AZN)

Legacy Capital Wealth Partners LLC raised its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 65.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,231 shares of the company’s stock after buying an additional 2,859 shares during the period. Legacy Capital Wealth Partners LLC’s holdings in AstraZeneca were worth $487,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Anchor Investment Management LLC acquired a new position in AstraZeneca during the 4th quarter worth $26,000. Compagnie Lombard Odier SCmA acquired a new stake in AstraZeneca during the 4th quarter worth $27,000. Nemes Rush Group LLC raised its position in shares of AstraZeneca by 375.6% during the 3rd quarter. Nemes Rush Group LLC now owns 428 shares of the company’s stock valued at $29,000 after acquiring an additional 338 shares during the last quarter. LWM Advisory Services LLC bought a new position in shares of AstraZeneca in the 3rd quarter worth $35,000. Finally, Arlington Trust Co LLC acquired a new stake in shares of AstraZeneca during the fourth quarter worth $37,000. Institutional investors own 20.35% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on AZN shares. Jefferies Financial Group cut shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, April 16th. Morgan Stanley started coverage on AstraZeneca in a research report on Tuesday, January 23rd. They issued an “overweight” rating for the company. Finally, BMO Capital Markets raised their target price on shares of AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a report on Friday. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.00.

AstraZeneca Stock Performance

AZN opened at $75.17 on Monday. The company has a quick ratio of 0.70, a current ratio of 0.89 and a debt-to-equity ratio of 0.73. The stock has a market cap of $233.06 billion, a price-to-earnings ratio of 36.85, a PEG ratio of 1.37 and a beta of 0.50. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $75.81. The business has a 50 day moving average of $67.27 and a 200-day moving average of $66.05.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.73 EPS for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.01). AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. The company had revenue of $12.02 billion during the quarter, compared to analyst estimates of $12.07 billion. During the same quarter last year, the company posted $0.69 EPS. The firm’s quarterly revenue was up 7.3% on a year-over-year basis. On average, equities research analysts expect that AstraZeneca PLC will post 4.01 earnings per share for the current year.

AstraZeneca Increases Dividend

The firm also recently disclosed a Semi-Annual dividend, which was paid on Monday, March 25th. Shareholders of record on Friday, February 23rd were paid a $0.965 dividend. This is a boost from AstraZeneca’s previous Semi-Annual dividend of $0.47. The ex-dividend date was Thursday, February 22nd. This represents a yield of 2.3%. AstraZeneca’s payout ratio is 94.61%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.